SCHEDULE: Perceptive Advisors Boosts Immatics Stake

Perceptive Advisors LLC and its affiliates have disclosed an increased beneficial ownership of Immatics N.V. ordinary shares, now holding 7.6% of the outstanding stock.

Summary

• Perceptive Advisors LLC, along with its affiliated entities Perceptive Life Sciences Master Fund, Ltd. and Joseph Edelman, have filed an amended Schedule 13D.
• The filing indicates that these entities collectively beneficially own 11,418,016 ordinary shares of Immatics N.V.
• This represents 7.6% of the total outstanding ordinary shares.
• The acquisition of 863,060 ordinary shares on August 26, 2026, was made using working capital from Perceptive Life Sciences Master Fund, Ltd. at a price of $8.69 per share.
• The filing also notes that Adam Stone, Chief Investment Officer of Perceptive Advisors LLC, holds stock options for 219,500 ordinary shares, with 171,500 currently exercisable or exercisable within 60 days.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a significant investment stake rather than a fundamental shift in the company's operations or outlook.

Positives

• Significant investment by a known investment firm (Perceptive Advisors) indicates confidence in Immatics N.V.'s potential.
• The acquisition of shares occurred during an underwritten offering, suggesting a potentially favorable entry point.
• The filing clarifies beneficial ownership, providing transparency to the market.

Negatives

• The filing does not provide specific details on the strategic intent behind the increased stake beyond investment.
• The information regarding Adam Stone's stock options is noted but doesn't directly impact the current beneficial ownership figures reported.

Risks

• The filing does not explicitly mention any new risks associated with this increased stake.
• Potential for future market activity by Perceptive Advisors that could influence share price.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Immatics N.V. It primarily reports on the investment position of Perceptive Advisors.

Management Comments

• The filing is a disclosure of beneficial ownership and does not contain direct quotes from Immatics N.V. management.
• Statements are made by Joseph Edelman, Managing Member of Perceptive Advisors LLC and Perceptive Life Sciences Master Fund, Ltd., certifying the accuracy of the filing.

Industry Context

StockSavvy.ai notes that significant stake disclosures by investment firms like Perceptive Advisors are common in the biotechnology and pharmaceutical sectors, often signaling conviction in a company's pipeline or technology. Immatics N.V. operates in the immuno-oncology space, a highly competitive and capital-intensive field.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant investor's stake may influence market perception and trading activity.
• Management: May face increased scrutiny or engagement from Perceptive Advisors regarding company strategy and performance.
• Potential Investors: The disclosure provides information about a substantial shareholder, which can be a factor in investment decisions.

Next Steps

• Monitor future filings from Perceptive Advisors for any further changes in their stake.
• Observe Immatics N.V.'s operational and clinical progress, which will be the primary driver of its stock performance.

Key Dates

Keywords

Immatics N.V., Schedule 13D, Perceptive Advisors, Beneficial Ownership, Ordinary Shares, Investment, Stock Options